Latest by Barbara Jungwirth
The impact of stigma on cognitive performance; risk factor dissonance among young black MSM; pregnancy and the HIV care continuum; new data on pediatric raltegravir use.
Real-world treatment efficacy high, but falls short of trials; parental communication and PrEP awareness among adolescent MSM; immunotherapy feasible in people with HIV and cancer; AIDS-defining illness increases mortality risk in lung cancer patients.
Black transgender women and the HIV care continuum; PrEP uptake potential among trans women; an update on U.S. mother-to-child HIV transmission; is extra measles vaccination necessary?
Loneliness, Depression, Financial Problems, and Comorbidities Top List of Issues Faced by Older Adults Living With HIV in New Report
Comorbidities, mental health issues, loneliness, and financial problems are the biggest issues faced by older people living with HIV, the San Francisco portion of a new report issued by the ACRIA Center on HIV and Aging at GMHC showed.
A cellphone attachment that detects HIV RNA; HIV-2 does indeed often progress to AIDS; CD4 count declines and incident hepatitis C coinfection; the global demographics of non-Hodgkin lymphoma.
High HIV prevalence among black MSM on PrEP; substance use reduction lessens depressive symptoms; correlations between pain symptoms and age; the impact of seroconversion and antiretroviral therapy on risk behaviors.
Use of the dapivirine vaginal ring for pre-exposure prophylaxis (PrEP) does not lead to resistance mutations in women who seroconvert, Urvi Parikh, Ph.D., reported at the HIV Research for Prevention 2018 conference.
The case for a new measurement of HIV treatment success; PrEP and HIV incidence in Australia; benefits of moderate exercise among older people with HIV; CD4 recovery rates after long-term viral suppression.
PrEP access appears far from equal in the U.S.; HIV treatment and viral suppression disparities in Europe; how today’s hepatitis C treatments affect mortality; sex-based differences in cognitive impairment.
A quadrivalent mosaic HIV vaccine induced greater immune responses on a variety of assays and against several HIV clades than its trivalent equivalent, as reported at the 2018 HIVR4P conference.